Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,572 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor suppressive role of the epigenetic master regulator BRD3 in colorectal cancer.
Hashimoto M, Masuda T, Nakano Y, Tobo T, Saito H, Koike K, Takahashi J, Abe T, Ando Y, Ozato Y, Hosoda K, Higuchi S, Hisamatsu Y, Toshima T, Yonemura Y, Hata T, Uemura M, Eguchi H, Doki Y, Mori M, Mimori K. Hashimoto M, et al. Cancer Sci. 2024 Jun;115(6):1866-1880. doi: 10.1111/cas.16129. Epub 2024 Mar 17. Cancer Sci. 2024. PMID: 38494600 Free article.
Spatial and single-cell colocalisation analysis reveals MDK-mediated immunosuppressive environment with regulatory T cells in colorectal carcinogenesis.
Hashimoto M, Kojima Y, Sakamoto T, Ozato Y, Nakano Y, Abe T, Hosoda K, Saito H, Higuchi S, Hisamatsu Y, Toshima T, Yonemura Y, Masuda T, Hata T, Nagayama S, Kagawa K, Goto Y, Utou M, Gamachi A, Imamura K, Kuze Y, Zenkoh J, Suzuki A, Takahashi K, Niida A, Hirose H, Hayashi S, Koseki J, Fukuchi S, Murakami K, Yoshizumi T, Kadomatsu K, Tobo T, Oda Y, Uemura M, Eguchi H, Doki Y, Mori M, Oshima M, Shibata T, Suzuki Y, Shimamura T, Mimori K. Hashimoto M, et al. EBioMedicine. 2024 May;103:105102. doi: 10.1016/j.ebiom.2024.105102. Epub 2024 Apr 12. EBioMedicine. 2024. PMID: 38614865 Free PMC article.
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Uchimoto T, Matsuda T, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Higashio T, Tsuchida S, Nishimura K, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Fujita K, Kimura T, Ohno Y, Shiroki R, Uemura H, Azuma H. Uchimoto T, et al. Among authors: hashimoto m. Target Oncol. 2024 May 28. doi: 10.1007/s11523-024-01068-7. Online ahead of print. Target Oncol. 2024. PMID: 38807017
Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study.
Hara S, Mori K, Fukuokaya W, Tomomasa N, Oguchi T, Takahashi Y, Saito S, Katami J, Sano T, Kadena S, Hashimoto M, Yata Y, Nishi E, Suhara Y, Takamizawa S, Kurawaki S, Suzuki H, Miyajima K, Iwatani K, Urabe F, Ito K, Yanagisawa T, Tsuzuki S, Shimomura T, Kimura T. Hara S, et al. Among authors: hashimoto m. Int J Clin Oncol. 2024 May 20. doi: 10.1007/s10147-024-02548-6. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38769191
4,572 results